Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Six RNAi-Related Patent Applications: Nov 22, 2006

Title: Method and Genetic Constructs for Modification of Lignin Composition of Corn Cobs
Number: 20060260011
Filed: March 24, 2006
Lead Inventor: Royston Carter, Syngenta Biotechnology
The invention, the patent application’s abstract states, “relates to methods and genetic constructs for the control of expression of enzymes involved in lignin biosynthesis in plants. The method involves the use of double-stranded RNAi to down-regulate or knock out the expression of the CAD and COMT genes. In particular embodiments the method involves the use of cob-specific or cob-preferred promoters for down-regulation of lignin biosynthesis in the cobs of corn plants.”

Title: Inhibition of SARS-Associated Coronavirus Infection and Replication by RNA Interference
Number: 20060258611
Filed: June 14, 2006
Lead Inventor: Hsiang-Fu Kung, University of Hong Kong
According to the patent application’s abstract, the invention relates to “therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome in humans. In particular, the present invention relates to RNA interference molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.”

Title: Method of Inhibition of Lipogenesis by Regulating PRP19 Expression
Number: 20060258609
Filed: May 9, 2006
Lead Inventor: Si-Young Cho, Amorepacific
“The downregulation of PRP 19 protein expression results in effectively reducing the expression of SCD1, the key lipogenic enzyme, and its downstream triacylglycerol synthesis enzymes, DGAT-1, and GPAT, as well as the intracellular content of neutral lipids, the major target for treating obesity,” the patent application’s abstract states.
The application specifically claims the use of an siRNA to inhibit PRP19 gene expression.

Title: RNAi Modulation of RSV and Therapeutic Uses Thereof
Number: 20060258608
Filed: April 26, 2006
Inventor: Rachel Meyers, Alnylam Pharmaceuticals
The invention, the patent application’s abstract states, “is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV mRNA levels, RSV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.”

Title: Methods and Sequences to Suppress Primate Huntington Gene Expression
Number: 20060257912
Filed: May 4, 2006
Lead Inventor: William Kaemmerer, Medtronic
According to its abstract, the patent application claims “sequences, molecules, and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease.”

Title: Use of siRNAs for Gene Silencing in Antigen-Producing Cells
Number: 20060257380
Filed: Sept. 19, 2002 PCT Filed: Sept. 19, 2002
Lead Inventor: Anne Galy, Institut Gustave Roussy
The invention, the patent application’s abstract states, “relates to the use of small interfering RNAs for silencing gene expression in antigen-presenting cells such as dendritic cells, in particular for immunomodulatory purposes.”

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.